PeerView Endocrinology & Diabetes CME/CNE/CPE Audio Podcast artwork

John B. Buse, MD, PhD - An Update on SGLT2 Inhibition for the Prevention and Treatment of Kidney Disease in Patients With Type 2 Diabetes

PeerView Endocrinology & Diabetes CME/CNE/CPE Audio Podcast

English - July 05, 2019 23:00 - 40 minutes - ★★★ - 4 ratings
Science cme medical education cme credits peerview insession inreview endocrinology diabetes cne Homepage Download Apple Podcasts Google Podcasts Overcast Castro Pocket Casts RSS feed
Previous Episode: Adrian Hernandez, MD, MHS - Recognizing and Treating Iron Deficiency in Patients With Heart Failure: Achieving Better Outcomes and Quality of Life
Next Episode: Evan J. Lipson, MD - Beyond the Basics of Immuno-Oncology: Navigating Clinical Challenges to Maximize the Benefits and Minimize the Risks of Cancer Immunotherapies

Go online to PeerView.com/XRN860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert in endocrinology discusses the clinical potential of SGLT2 inhibitors for the prevention and treatment of kidney disease in patients with type 2 diabetes. Upon completion of this activity, participants should be better able to: Review the proposed mechanism(s) that support the clinical potential of SGLT2 inhibitors to provide renal protection in patients with type 2 diabetes, Assess the evidence evaluating the potential of SGLT2 inhibitors to prevent and/or treat kidney disease in patients with type 2 diabetes.